Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 5/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.58 |
| ▸ | CCR2 | P41597 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13439703 | 1.00 | ROCK1 (0.58) | ROCK1ROCK2CCR2KCNH2BCHE | |
| SCHEMBL13439728 | 0.87 | ROCK1 (0.58) | ROCK1ROCK2CCR2KCNH2BCHE | |
| SCHEMBL13439723 | 0.87 | ROCK1 (0.58) | ROCK1ROCK2CCR2KCNH2BCHE | |
| SCHEMBL9598403 | 0.87 | ROCK1 (0.65) | ROCK1ROCK2CCR2KCNH2BCHE | |
| SCHEMBL11729293 | 0.86 | ROCK1 (0.61) | ROCK1ROCK2CCR2KCNH2BCHE | |
| SCHEMBL13463050 | 0.85 | ROCK1 (0.60) | ROCK1ROCK2CCR2KCNH2BCHE | |
| SCHEMBL13439718 | 0.85 | SMN1; SMN2 (0.67) | ROCK1ROCK2CCR2HRH3MAOB | |
| SCHEMBL23475058 | 0.81 | HRH3 (0.52) | HRH3MAOBMEN1KMT2A | |
| SCHEMBL23474933 | 0.81 | HRH3 (0.52) | HRH3MAOBMEN1KMT2A | |
| SCHEMBL23475095 | 0.81 | HRH3 (0.52) | HRH3MAOBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674828-B2 | Urea antagonists of P2Y1receptor useful in the treatment of thrombotic conditions | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-09 | — | — | US | disclosed |
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
| US-7388021-B2 | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280905-A1 | UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS | P2RY1, P2RY11, P2RY2 | ROCK1 2941/4885ROCK2 4396/4885CCR2 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.